Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis stock inched higher Tuesday after the firm hiked its earnings outlook for the third time this year following its Sandoz spinoff.

Novartis Hikes Its Earnings Outlook For The Third Time This Year

Novartis AG (NVS) Shareholder Analyst Call (Transcript)

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its generic drugs unit.

Novartis Begins New Era With Profit Beat and Guidance Hike

Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.

Novartis lifts 2023 earnings forecast for third time

Sandoz Group AG

Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing operations 2 Q 3 sales grew +12% (cc, +12% USD) with core operating income growing +21% (cc, +17% USD) Growth driven by continued strong performance from Kesimpta (+124% cc), Entresto (+31% cc), Kisqali (+76% cc), Pluvicto (+217% cc) and Scemblix (+157% cc) Q3 operating income grew +13% (cc, -4% USD) driven by higher sales and lower restructuring charges, partly offset by higher impairments through discontinuation of early stage development projects Q3 net income grew +37% (cc, +14% USD) mainly due to higher operating income Q3 free cash flow 3 was USD 5.0 billion (+24% USD) driven by higher net cash flows from operating activities Q3 core EPS grew +29% (cc, +24% USD) to USD 1.74 Strong nine months performance with sales growing +10% (cc, +8% USD) and core operating income growing +19% (cc, +13% USD) Q3 key innovation milestones, including positive Ph3 data for multiple pipeline assets with blockbuster potential: Cosentyx – FDA approval for intravenous formulation in three indications (PsA, AS, nr-axSpA)

Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance

Basel, October 23, 2023 — Novartis today presents data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI1.

Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting

Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.

Novartis (NVS) to Report Q3 Earnings: What's in the Offing?

Gilead Sciences

Haleon PLC

Medtronic

Merck

West Pharmaceutical Services

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

Basel, October 20, 2023 — Novartis will present late-breaking results from a prespecified exploratory subgroup analysis of invasive disease-free survival (iDFS) from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2023. After 27.7 months of follow-up, the iDFS benefit with Kisqali® (ribociclib) plus endocrine therapy (ET) was consistent across key prespecified subgroups, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) (see table below)1. Results were also consistent with those in the overall trial population, reinforcing that the benefit was not driven by a specific patient subgroup1 ,2.

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Bristol-Myers

Bristol Myers is turning to acquisitions and its pipeline to offset a major patent cliff. Novartis just completed a spinoff that should lead to stronger overall growth.

2 Biotech Stocks That Could Make You Richer

Microsoft

Visa

Novartis, Visa, and Microsoft are three highly profitable businesses that generate excellent margins. These companies are also focused on growing and getting bigger over the years.

3 Unstoppable Stocks to Buy and Hold for Decades

The latest trading day saw Novartis (NVS) settling at $97.87, representing a -1.55% change from its previous close.

Novartis (NVS) Suffers a Larger Drop Than the General Market: Key Insights

Eli Lilly

McKesson

Although healthcare stocks lag other sectors, large-cap leaders such as  Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS  are in possible buy ranges as they get moving-average support.

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

UK-based biotech firm AstronauTx has secured £48 million ($61 million) in a significant Series A funding round, marking a step towards developing treatments for Alzheimer's and other neurodegenerative diseases, according to the Financial Times. Spun out of University College London in 2019, the company initially focused on astrocytes, brain support cells crucial for neuron health.

Novartis leads funding round for UK Alzheimer's specialist

Novartis (NVS) closed at $97.14 in the latest trading session, marking a +1.03% move from the prior day.

Novartis (NVS) Ascends But Remains Behind Market: Some Facts to Note

Pfizer

AstraZeneca

Moderna

CRISPR Therapeutics

GlaxoSmithKline

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started trading with a market cap of $11.2 billion. The company has now completed its business transformation. We expect positive pipeline readouts; however, Novartis's valuation looks full.

Novartis: Better Margin Visibility Ex-Sandoz

Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Swiss drug giant Novartis AG (ADR) (NYSE:NVS) has just completed the spin-off of Sandoz, its generics and biosimilars business. Kelloggs has done the same, hiving off its cereal business into WK Kellogg Co this week, and renaming the remaining snacks and frozen food business Kellanova.

Spin-outs on the rise as companies try to win out in desolate M&A market

Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.

Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook

Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!

SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today

Swiss drugs giant Novartis AG has completed the spin-off of its generics business Sandoz, which made an underpowered stock market debut. From an IPO price of 24 Swiss Francs, the stock drifted down to 23.82 Swiss Francs.

Novartis spin-off completed as Sandoz makes subdued start on Swiss bourse

Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.

Novartis unit Sandoz set to start trading after completing spinoff

Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.

News for Novartis Stock (NVS)